Trials / Completed
CompletedNCT04267380
A Study To Compare The Effectiveness Of Tofacitinib 11 Mg Once A Day To Tofacitinib 5 Mg Twice A Day
Compare Effectiveness of Tofacitinib 11 mg QD to Tofacitinib 5 mg BID
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 298 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 0 Years
- Healthy volunteers
- Not accepted
Summary
It is hypothesized that patients prescribed tofacitinib 11 mg Modified Release (MR) formulation once daily (QD) will achieve similar benefit to those prescribed tofacitinib 5 mg twice a day (BID) dosage in real world use. This study will therefore seek to compare the effectiveness of the MR 11 mg QD regimen to the IR 5 mg BID regimen for the treatment of RA in a real-world registry of RA patients.
Conditions
Timeline
- Start date
- 2018-09-30
- Primary completion
- 2019-08-31
- Completion
- 2019-08-31
- First posted
- 2020-02-12
- Last updated
- 2023-05-22
- Results posted
- 2020-09-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT04267380. Inclusion in this directory is not an endorsement.